Clinical trials: Resectable Esophageal Cancer
Esophageal Squamous Cell Carcinoma
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
- Trial name
- ESCC (NCT06601309)
- Testing
- Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Medical University Union Hospital
Esophagus Cancer
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group
- Trial name
- NCT07046221
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, cis-platinum
- Volunteers
- 60 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death ligand 1(PD-L1) immunotherapy, Adebrelimab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant…
- Trial name
- NCT06225921
- Testing
- Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the outcomes and identify predictors of neoadjuvant anti-PD-1 plus chemotherapy in locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT05740995
- Testing
- neoadjuvant anti-PD-1 plus chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Neoplasm
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
In patients with esophageal cancer, treatment with curative intent can be given to medically fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone or in combination.
- Trial name
- LERFOX-C (NCT02636088)
- Testing
- Cetuximab
- Volunteers
- 51 people
- Sponsor
- Gabriella Alexandersson von Döbeln
Esophageal Cancer
Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
This study will evaluate if proton beam therapy as part of chemoradiation results in a decrease in diffusion lung capacity of carbon monoxide (DLCO) compared to photon radiation therapy for esophageal carcinoma.
- Trial name
- ES01 (NCT03234842)
- Testing
- Proton Beam Therapy, Photon Radiation Therapy, Chemotherapy
- Where
- United States
- Sponsor
- University of Florida
Esophageal Diseases
Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus
This study is designed pre-operative for patients with resectable, local-regional carcinoma of the esophagus.
- Trial name
- NCT00208936
- Testing
- Taxol, Cisplatin, 5-Fluorouracil, G-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA).
- Conditions
- Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma
- Trial name
- NeoTISLEGA (NCT07059299)
- Testing
- Tislelizumab, FLOT Chemotherapy
- Where
- 4 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophageal Cancer
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer
The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced resectable…
- Trial name
- NCT05547529
- Testing
- Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy., Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
- Where
- Russia
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Esophageal Squamous Cell Carcinoma
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
NICE-RT study is a "safety run-in" and phase II trial evaluating the safety and efficacy of Camrelizumab combined with Nab-paclitaxel and Carboplatin and Radiotherapy in patients with resectable locally advanced esophageal…
- Trial name
- NCT05650216
- Testing
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery
This phase III trial studies nutritional supplementation with Impact Advanced Recovery to see how well it works compared with standard nutritional supplementation in reducing complications in patients with esophageal cancer that…
- Conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8
- Trial name
- NCT04029857
- Testing
- Nutritional Supplement Drink, Nutritional Supplementation
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma Resectable
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma
A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone for esophageal cancer.
- Trial name
- NCT01688700
- Testing
- Nimotuzumab combined with paclitaxel and cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Resectable Esophageal Squamous Cell Carcinoma
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Evaluating the efficacy and safety of PD-L1 (Programmed Death-L1)antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 (clinical stage tumor 1b-2) esophageal squamous cell carcinoma
- Trial name
- NCT06599775
- Testing
- Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection
- Volunteers
- 42 people
- Sponsor
- Shanghai Zhongshan Hospital
Resectable Esophageal Cancer
Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC
This study was a single-arm, two-cohort, phase II trial aimed at evaluating the efficacy and safety of FAPI-PET/CT response for guiding the selection of neoadjuvant treatment modes after chemotherapy combined with immunotherapy.
- Trial name
- FAIR (NCT07385664)
- Testing
- Neoadjuvant Chemoimmunotherapy or Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ji Yongling
Stomach Cancer
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
Perioperative chemotherapy improves overall survival (OS) and disease-free survival (DFS) compared with surgery alone in patients with resectable gastric adenocarcinoma (GA) or gastro-oesophageal junction adenocarcinoma (GEJA).
- Trial name
- NCT04819971
- Testing
- Tirelizumab, Trastuzumab, Docetaxel
- Where
- China
- Volunteers
- 67 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04506138
- Testing
- Camrelizumab, Paclitaxel for Injection (Albumin Bound), Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Neoplasms, Esophageal Diseases
Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable esophageal squamous cell carcinoma
- Trial name
- NCT03200691
- Testing
- 3-DCRT or IMRT radiation, anti-PD-1 antibody SHR-1210
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hangzhou Cancer Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Palbociclib, as a new neoadjuvant treatment…
- Trial name
- NCT06654297
- Testing
- Camrelizumab, Palbociclib(100mg), Palbociclib(125mg)
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it.
- Trial name
- NCT04850729
- Testing
- non-intervention
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Nanfang Hospital, Southern Medical University